Lyme Disease Halifax

Lyme Disease – Information on Lyme Disease- Life stories of Lyme disease

Browsing Posts tagged NIH

Page 1 of 3
November 28th, 2012
Dear Nova Scotia MLA/MP:
RE: Lyme Disease in Nova Scotia
Lyme Disease (LD) is an emerging disease in Nova Scotia and Canada that is generating considerable attention from the media, advocacy groups and communities. Given this situation, I felt it important that you had accurate and up-to-date information on LD in Nova Scotia and the provincial response plan.
LD is a bacterial illness that can be transmitted to humans through the bite of a blacklegged tick (deer tick). There are a number of tick species in Nova Scotia, but only the blacklegged tick can carry the bacteria that can cause LD. Not all blacklegged ticks carry the bacteria and the risk of acquiring LD remains low in the province. LD is readily treatable with appropriate antibiotics.
The Department of Health and Wellness (DHW) has an active LD response plan which includes an interdisciplinary committee (public health, veterinary medicine, wildlife biology) that provides evidence-based advice and guidance to the provincial government on the control of LD. Nova Scotia has multiple infectious disease and medical microbiologist experts in the province who deal with treatment and diagnosis of LD. DHW has a close working relationship with these clinical experts through an Infectious Disease Expert Group, which meets regularly to advise DHW on public health and infection control issues. We also work closely with our partners at the Public Health Agency of Canada and the National Microbiology Laboratory who provide evidence based recommendations for the prevention and surveillance of LD and ticks.
Tick and Lyme Disease Surveillance
Lyme disease is a notifiable disease under the National Microbiology Laboratory. Health care professionals are required to report cases of Lyme disease to Public Health when they diagnose clients clinically or with laboratory confirmation. In 2011, there were 54 confirmed cases of LD reported to Public Health, corresponding to an incidence rate of 5.8 cases per 100,000 population. Surveillance of both human cases and blacklegged ticks in the province enables DHW to keep abreast of the current state of Lyme disease in Nova Scotia.
Over the past few years, DHW together with the Department of Natural Resources and the Public Health Agency of Canada have been identifying and testing ticks collected in Nova Scotia. Analysis of this data has identified six areas where blacklegged ticks carrying the bacteria that can cause LD are known to be endemic (i.e. have become established as part of the local ecology). These endemic locations are areas in Yarmouth County, Shelburne County, Lunenburg County, Halifax County, Pictou County and most recently Queens County. These known endemic areas can be found on the Department of Health and Wellness website at http://www.gov.ns.ca/hpp/cdpc/lyme.asp
DHW has had a tick surveillance program in place since 2002, which included both passive (ticks being submitted by the public) and active plans. In the fall of 2011, DHW restructured its tick surveillance program to place an emphasis on active surveillance. Active surveillance involves ‘in the field’ work including small mammal testing and dragging vegetation to collect
Page 2 of 3
ticks. We will continue with focused active surveillance to determine additional areas where ticks may be establishing.
It is expected the number of LD cases will increase over time as ticks become more densely populated and expand their geographical range when conditions permit. Climate change related to global warming is expected to contribute to the increase of LD in Nova Scotia and Canada.
Public Information
DHW regularly provides consistent, evidence based information about LD and its prevention to the public. Strategies are implemented each year to provide Nova Scotians with information about the prevention of tick bites and to ensure health care providers have the most up to date clinical information. The DHW website is regularly updated plus we work closely with partners to disseminate information regarding LD to the public and stakeholders via various methods (letters via schools, residential letters, media releases, websites, signs in parks/campgrounds). DHW has also provided an advertorial for newspapers as well as news release each year. DHW regularly responds to multiple media requests and letters to government regarding LD.
Nova Scotians and visitors to the province can help prevent exposure to blacklegged ticks and LD by taking some simple precautions. This is especially important when in areas where there may be increased risk. Prevention messages can be found on the DHW website at: http://www.gov.ns.ca/hpp/cdpc/lyme.asp
Information to Clinicians
Webinars have been provided to health care providers in the last few years, addressing prevention, surveillance, diagnosis and treatment of LD. In addition, the DHW provides updates to physicians in the province via Doctors Nova Scotia. The Infectious Disease Expert Group has developed a document entitled “Statement for Managing Lyme Disease in Nova Scotia” which has been widely circulated to physicians in the province. This document is based on current evidence and follows the guidelines endorsed by the Infectious Disease Society of America.
Testing
Laboratory testing for LD in Nova Scotia follows the guidelines established by the Public Health Agency of Canada and the Centre for Disease Control and Prevention in the United States. These guidelines have been endorsed by the Canadian Public Health Laboratories Network and the Infectious Diseases Society of America.
We are aware of the Canadian Lyme disease advocacy group, Can Lyme, who claim that the testing and treatment of LD is inadequate. However, the testing methods they promote, and the ones used by many private labs in the US, are not endorsed by infectious disease and laboratory experts.
Research
DHW supports and partners with many researchers in the field of LD and tick surveillance. Research that DHW is aware of and supports includes the Public Health Agency of Canada’s study on identification of emerging endemic areas for the blacklegged tick and prediction of the further spread of LD. Two other research initiatives that DHW supports include the human seroprevalence study on LD and the Deer Treatment Study. We are aware that other
Page 3 of 3
researchers initiate studies within the province with or without consultation or consideration of experts on the interdisciplinary committee.
If you have additional questions regarding LD, or if you would like to involve a regional Medical Officer of Health in any meetings with community or advocacy groups, please contact your local Public Health office which can be found through the following website: http://novascotia.ca/DHW/about/phs-offices.asp
We appreciate your ongoing support and cooperation to help ensure Nova Scotians receive evidence-based information on LD.
Sincerely,
Robert Strang MD, MHSc., FRCPC
Chief Medical Officer of Health
c. Dr. Frank Atherton – Deputy Chief Medical Officer of Health, Health and Wellness
Elaine Holmes, Director – Communicable Disease Prevention and Control, Health and Wellness
Regional Medical Officers of Health

— Will Carry Out Clinical Trials with Blood Systems Research Institute, Creative Testing Solutions —

BOSTON, MA — September 10, 2012 — Immunetics, Inc., has received a $3.7 million, two year SBIR contract from the National Heart, Lung and Blood Institute, an agency of the National Institutes of Health (NIH), to support clinical trials of a new blood screening test for Babesia infection.

“Babesia is among the top infectious threats to blood safety and, at present, there is no licensed test available. The NIH contract will allow us to address this gap in blood safety with the first cost-effective test designed for high-throughput screening of the blood supply.  We are honored to have been entrusted by NIH to carry out this public health mission,” said Andrew E. Levin, Ph.D., Immunetics Chief Executive Officer and Scientific Director.

Babesia is a parasite which is transmitted by the same ticks that transmit Lyme disease. While it is often asymptomatic in healthy people, Babesia infection can lead to severe or fatal illness, especially in immunocompromised patients. The parasites can remain viable in blood donations and infect transfusion recipients. In recent years, nine fatal cases of transfusion-transmitted babesiosis have been reported. Surveillance carried out by the Centers for Disease Control and Prevention (CDC) revealed over 1,000 cases of infection nationwide in 2011 — a number that appears to be growing. The US Food & Drug Administration (FDA) sponsored a workshop in 2008 focused on Babesiosis as an emerging threat to the blood supply, and the Blood Products Advisory Committee convened a meeting in 2010 to advise the FDA on approaches to blood screening for Babesia.

The contract award will enable Immunetics to bring its Babesia test, developed under initial NIH support, through clinical trials and regulatory licensure. The trials will be carried out in collaboration with Blood Systems Research Institute of San Francisco, Calif., and Creative Testing Solutions of Tempe, Ariz. Creative Testing Solutions currently tests about 25% of the US blood supply, including regions endemic for the parasitic agent. The Babesia test will initially be made available through Creative Testing Solutions’ laboratories.

“We look forward to partnering with Immunetics and BSRI in the development and FDA approval process of a Babesia assay for use in blood screening,” said Creative Testing Solutions President Sally Caglioti. “It is always our intent to offer innovative services that provide our customers with the best donor testing possible. Active collaboration in the development of diagnostic tests that fit the immediate needs of the blood banking community is the next logical step to support CTS’ mission.”

“When the screening test identifies antibody-reactive donors, we will enroll and conduct rigorous testing of donation-derived and follow-up samples from those donors so that we can more fully understand the natural history of Babesia infection in asymptomatic donors,” said Michael P. Busch, M.D., Ph.D., Blood Systems Research Institute Director and Senior Vice President for Research and Scientific Affairs at Blood Systems. “The information that we derive will help guide the development of policies on how the test can be used most effectively. It will also determine whether and how donors who have had a positive result on the screening test could safely donate in the future.”

For more information, visit the company’s website at http://www.immunetics.com or call 1-617-896-9100 or toll-free 1-800-227-4765.

Immunetics is a leading developer and provider of innovative tests for a variety of bacterial, viral, and parasitic diseases. Recently, the company received FDA clearance for its BacTx® test for bacterial contamination in platelets. The company has developed and markets other FDA-cleared products, including a test for Lyme disease, and is actively working on new tests for HIV and Chagas disease — both of which are known or emerging risks to the blood supply.

See full Article:

http://www.immunetics.com/pr_120910.html